Partnerships: Industry & Academic

Engaging Industry and Academic Partners

CCTG is know for cancer clinical trial research and is the world's largest cooperative collaborative oncology group. Our success is realized through our network of investigators who develop scientifically important and meaningful trials, conducted both rapidly and to rigorous standards. With over 40 years of experience there is no network that rivals the depth and breadth of operations with a global reputation for rapid execution of quality clinical trials.


National and international collaboration

Industry partnerships

While CCTG trials are independently conducted, analyzed and reported. Pharmaceutical or academic drug manufacturers provide CCTG access to their investigational new drugs because they recognize the high quality research being conducted through the group.

Janet Dancey, Director of CCTG

Canadian Cancer Trials Group awarded $25 million in funding to support clinical trials

The CCTG has been awarded more than $25 million CAD from the U.S. National Institutes of Health and National Cancer Institute.

More >>

CCTG receives matching infrastructure award from The Ontario Research Fund

(left to right) Shakeel Virk, Director Operations & Pathology Coordinator of the CCTG Tumour Tissue Data Repository, Dr David LeBrun, Academic Director, Queen's Laboratory for Molecular Pathology, Ms. Sophie Kiwala, MPP for Kingston and the Islands, Dr Lois Shepherd Director of the CCTG Tumour Tissue Data Repository, Dr. Madhuri Koti, Queen's University (back) Dr. John Fisher, Vice-Principal (Research), Queen’s University.

Queen's University played host to a research funding announcement with Dr.

More >>
Cancer Research Institute and Canadian Cancer Trials Group Announce Strategic Collaboration

Cancer Research Institute and Canadian Cancer Trials Group Announce Strategic Collaboration

The Cancer Research Institute (CRI) and the Canadian Cancer Trials Group (CCTG) have announced a multi-year collaboration to develop and conduct clinical trials in immunotherapy.

More >>
Dr. Janet Dancey, CCTG Director and JELF award recipient

Precision Oncology takes a step forward at CCTG

The Canadian Foundation for Innovation (CFI) John R. Evans Leaders Fund (JELF) has announced a funding award of $197,065 to allow the Canadian Cancer Trials Group (CCTG) to acquire a state-of-the-art digital histology slide scanner.

More >>